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Abstract
Background: Vasodilator-stimulated phosphoprotein (VASP) mediates focal adhesion, actin filament binding and
polymerization in a variety of cells, thereby inhibiting cell movement. Phosphorylation of VASP via cAMP and
cGMP dependent protein kinases releases this "brake" on cell motility. Thus, phosphorylation of VASP may be
necessary for epithelial cell repair of damage from allergen-induced inflammation. Two hypotheses were
examined: (1) injury from segmental allergen challenge increases VASP phosphorylation in airway epithelium in
asthmatic but not nonasthmatic normal subjects, (2) regular in vivo β2-agonist use increases VASP phosphorylation
in asthmatic epithelium, altering cell adhesion.
Methods: Bronchial epithelium was obtained from asthmatic and non-asthmatic normal subjects before and after
segmental allergen challenge, and after regularly inhaled albuterol, in three separate protocols. VASP
phosphorylation was examined in Western blots of epithelial samples. DNA was obtained for β2-adrenergic
receptor haplotype determination.
Results: Although VASP phosphorylation increased, it was not significantly greater after allergen challenge in
asthmatics or normals. However, VASP phosphorylation in epithelium of nonasthmatic normal subjects was
double that observed in asthmatic subjects, both at baseline and after challenge. Regularly inhaled albuterol
significantly increased VASP phosphorylation in asthmatic subjects in both unchallenged and antigen challenged
lung segment epithelium. There was also a significant increase in epithelial cells in the bronchoalveolar lavage of
the unchallenged lung segment after regular inhalation of albuterol but not of placebo. The haplotypes of the β2-
adrenergic receptor did not appear to associate with increased or decreased phosphorylation of VASP.
Conclusion: Decreased VASP phosphorylation was observed in epithelial cells of asthmatics compared to
nonasthmatic normals, despite response to β-agonist. The decreased phosphorylation does not appear to be
associated with a particular β2-adrenergic receptor haplotype. The observed decrease in VASP phosphorylation
suggests greater inhibition of actin reorganization which is necessary for altering attachment and migration
required during epithelial repair.
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Background
Attachment and migration of airway epithelial cells is an
important aspect of repair of injury induced by allergens
and other agents in asthma. Cytoskeletal reorganization,
mediated through actin filament remodeling, is required
to facilitate attachment and migration of epithelial cells
into damaged areas. The vasodilator-stimulated phospho-
protein (VASP) binds to profilin, F- and G-actin, and
mediates actin assembly, bundling and attachment at
focal adhesions [1,2]. VASP and two other members of the
ENA/VASP family in mammalian cells, MENA (mamma-
lian ENAbled) and EVL (ENA/VASP-like) slow or inhibit
fibroblast motility by altering the dynamics of actin fila-
ment structure [3,4]. However, MENA and EVL, despite
shared molecular similarities and normal expression, did
not substitute for VASP and reverse compromised cell
motility in a wound healing assay of VASP-/- fibroblasts
[5].
VASP phosphorylation occurs on two serine and one thre-
onine (Ser 157, Ser 239 and Thr 278) through cAMP and
cGMP dependent protein kinases A and G [6-9], and as
recently observed in smooth muscle cells, protein kinase
C [10]. Phosphorylation by cAMP protein kinase prefer-
entially occurs at Ser 157, whereas phosphorylation by
cGMP protein kinase preferentially occurs at Ser 239, both
kinases secondarily acting on Thr 278 [7]. The Ser 157
phosphorylation results in decreased migration of the
VASP molecule from 46 KD to 50 KD in SDS-gel electro-
phoresis [6-9]. Functionally, phosphorylation of VASP
regulates its interaction with actin, and correlates with
detachment and spreading of fibroblasts and epithelial
cells [3,4,9,11,12]. Thus, the ratio of the 50 KD to the 46
KD molecular form of VASP within a cell sample provides
a measure of VASP phosphorylation and indicates active
remodeling of the actin cytoskeleton during cell attach-
ment and migration.
We postulated that repair of injury to the airway epithe-
lium during antigen-induced inflammation would
involve enhanced phosphorylation of VASP in order to
mediate actin cytoskeleton remodeling and cell migration
into damaged areas. We further hypothesized that inhala-
tion of the β-agonist albuterol, would also increase phos-
phorylation of VASP by stimulation of cAMP-dependent
protein kinase activity, and result in altered epithelial cell
attachment and mobility. These hypotheses were tested in
three protocols using brush samples of airway epithelium
obtained from allergic asthmatics and control subjects.
Methods
Subjects and bronchoscopic protocols
Thirty-one individuals characterized as mild allergic (to
ragweed) asthmatics based on American Thoracic Society
criteria, and 17 nonasthmatic, normal healthy subjects
volunteered for the studies approved by the Wake Forest
University School of Medicine or the Jefferson Medical
College Institutional Review Boards. All volunteers gave
informed, written consent to screening, bronchoscopic
procedures and characterization as previously described
[13,14]. Asthmatics had mild intermittent asthma and 29
of the 31 were using only inhaled β2-agonist on an as
needed basis; the remaining 2 asthmatics were using
chronic inhaled steroid and long-acting β2-agonist ther-
apy. These latter two subjects contributed bronchial epi-
thelial cells only to "c" protocol (see below) and DNA for
β-adrenergic receptor haplotyping. Characterization of all
subjects included collection of demographic information,
standard spirometry, airway reactivity to methacholine,
skin reactivity to ragweed allergen (short ragweed antigen,
Greer Laboratories, Lenoir, NC) as previously described
[14], and β-adrenergic receptor haplotyping. Results for
other investigations on some of the subjects in these stud-
ies have been reported: leukocytes and inflammatory
mediators (TGFβ1, TGFβ2, IL-4, IL-10, IL-13, sphingosine
1-phosphate, sVCAM) in lavage fluid induced by segmen-
tal allergen challenge, TRAIL and its receptors, induction
of stress proteins in epithelial cells, epithelial cell prolifer-
ation and stimulation of fibrogenesis, and β2-adrenergic
receptor signaling [13-22]. Subject demographic and pul-
monary function data are listed in Table 1.
Table 1: Subject demographics. Data are presented as mean ± SEM except for PC20 methacholine which are presented as the 
geometric means.
Characteristics Allergic Asthmatic Nonasthmatic Normal P Value
Number: 31 17
Gender: 17 M/14 F 12 M/5 F
Age (yr): (range) 29.6 ± 1.3 (20 – 47) 27.1 ± 1.3 (21 – 33) P = 0.22
Ragweed Skin Tests Positive Negative
FEV1 (L): 3.33 ± 0.2 4.06 ± 0.2 P = 0.005
FEV1 (% predicted): 84.8 ± 6 101.3 ± 3.7 P = 0.07
PC20 Methacholine (mg/ml): 1.0 ± 0.8 16 at > 32 mg/ml
1 at 11 mg/ml
Serum IgE (IU/ml): 177 ± 1 51 ± 13 P = 0.002Respiratory Research 2006, 7:25 http://respiratory-research.com/content/7/1/25
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Bronchoalveolar lavage (BAL) and brush biopsies of bron-
chial epithelium from asthmatic or control subjects were
obtained in three separate protocols: (a) before (desig-
nated as day 1) and 24 hr, 1 week and 2 weeks after seg-
mental allergen challenge (SAC) (days 2, 9 and 16,
respectively) in a recovery from injury protocol (Table 2)
(n = 16: 9 asthmatics, 7 nonasthmatic normals); (b)
before (day 1) and 24 hr after SAC (day 2) at baseline,
repeated sampling before and 24 hr after SAC (days 18
and 19) after a two week period of regular inhaled β2-ago-
nist (albuterol) or placebo, and final repeat sampling (day
25) of initial lung segments after 1 additional week of β2-
agonist or placebo, withdrawn 12 hours prior to bron-
choscopy (Table 3) (n = 7 asthmatics on β2-agonist and a
repeat of n = 4 asthmatics on placebo); and (c) baseline
bronchoscopy on asthmatics (n = 16) and nonasthmatic
normals (n = 10). All subjects in protocols "a" and "c"
received albuterol just prior to bronchoscopy; those sub-
jects enrolled in "b" protocol received albuterol just prior
to bronchoscopy only after the two-week period of regular
inhaled β2-agonist (days 18 and 19). Bronchoscopy with
allergen challenge (Ag challenge) was preformed as previ-
ously described in detail using 10 ml of a 100X concentra-
tion of the minimum antigen dose giving a positive skin
test (wheal ≥ 10 mm with 0.001 RWAU/ml) [23]. For
bronchoalveolar lavage, 3 aliquots of 50 mls sterile nor-
mal saline (warmed to 37°C) were instilled and removed
by gentle suction. Brush biopsies of epithelium were
obtained from 2–3 cytology brushings combined and
processed as reported in detail and below [18,19].
Cells from BAL fluid were pelleted, resuspended and
counted [21]. Aliquots of BAL cells (105 cells) from the
autologous lung segment were added to medium in wells
surrounding semiporous membrane culture inserts (0.4
µm pore size, Millicell-12 mm HA MCE; Millipore, Bed-
ford, MA) containing the epithelial cell aliquots for co-
culture. Cytospin preparations of BAL cells were stained,
and differential counts for epithelial cells (Alcian Blue, cil-
iated, or other columnar cells, and their sum = "total" epi-
thelial cell counts) were calculated (×104/ml).
Epithelial cell culture and western blot analysis of VASP
Bronchial epithelial cells were cultured 24 hr at air/fluid
interface in Millicell culture inserts either without or with
105 BAL cells added to the well surrounding the insert to
maintain contact with soluble inflammatory mediators
from leukocytes of the same lung segment [18]. Inserts
containing epithelial cells were harvested in RIPA buffer
(phosphate buffered saline containing 1% NP40, 0.5%
sodium deoxycholate, 1% sodium dodecyl sulfate, with
protease inhibitors: 0.1 mg/ml PMSF, aprotinin and 1
mM sodium orthovanadate). Cell lysates were frozen
until analyzed by SDS-PAGE and Western blotting
[18,19]. Western blots were developed with monoclonal
anti-VASP antibody, recognizing both the 46 kD and 50
Table 2: Recovery from injury bronchoscopy protocol. Samples (lavage and brush biopsies) from four bronchoscopic procedures on 
each of 9 asthmatic and 7 nonasthmatic normal subjects were obtained from unchallenged and antigen (Ag) challenged lung segments 
according to the procedure day as indicated. A second Ag challenge on day 2 was performed to provide an additional challenged 
segment for day 9 without compromise from prior sampling.
P r o c e d u r e  D a y : 1291 6
Lung Segment:
Left Lower (Unchallenged Seg) Sample
Right Middle (Challenged Seg 1) Ag Challenge Sample Sample
Lingula (Challenged Seg 2) Ag Challenge Sample
Table 3: β2-agonist or placebo regular inhalation and bronchoscopy protocol. Samples (lavage and brush biopsies) from five 
bronchoscopic procedures were obtained from the unchallenged and Ag challenged lung segments according to the procedure day 
indicated. Seven asthmatics enrolled in the drug arm, and 4 of these same subjects re-enrolled in the placebo arm. A baseline sample 
and a 24 hr post Ag challenge sample were obtained before (days 1 and 2) and after (days 18 and 19) a two week period of regular 
albuterol or placebo use. The initial baseline unchallenged and challenged lung segments were resampled following one additional 
week of regular albuterol or placebo use which were discontinued 12 hr before the final bronchoscopic procedure on day 25.
Procedure Day: 1 2 3–17 18 19 20–24 25
Lung Segment:
Lingula (Unchallenged) Sample Sample
RML (Challenged) Challenge Sample Sample
Albuterol 2 puffs, qid
RLL (Unchallenged) Sample
LLL (Challenged) Challenge Sample
Albuterol 2 puffs, qidRespiratory Research 2006, 7:25 http://respiratory-research.com/content/7/1/25
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kD (phosphorylated at Ser 157) molecular forms (Trans-
duction Laboratories, Lexington, KY) (see Figure 1), and
quantitated by densitometry (Kodak 1D Image Analysis
System). This previously reported method [18] provides a
linear response for band densities of the 50/46 KD VASP
over the range of epithelial cell protein concentration
examined.
To ascertain that epithelial cells of asthmatics were
responsive to β2-agonists, aliquots of epithelial cells from
some asthmatics were stimulated for 2 hr after the initial
24 hr incubation with in vitro addition of albuterol (10-7
M), salmeterol (10-7 M) or no stimulus before harvest and
handling as described above.
Haplotyping of β2-adrenergic receptor
DNA was isolated from cell pellets or lysates, amplified by
GenomiPhi DNA kit (Amersham Biosciences, Piscataway,
NJ)[24] if low in yield, and haplotyped for the β-adrener-
gic receptor according to the multiplex ARMS PCR assay
[25]. DNA of 11 asthmatics and 7 nonasthmatic normals
were sequenced by standard methodology [26] for the β-
adrenergic receptor in addition to haplotyping to confirm
haplotype assignment at the 13 SNP sites defined by Drys-
dale et al. [27].
Statistical analysis
Data were tested for normal distribution and equal vari-
ances by Sigmastat (version 2.0) and examined by one- or
two-way repeated measures analysis of variance, post hoc
pairwise comparisons by Tukey test at individual points,
paired or unpaired t test, as appropriate. A p < 0.05 was
considered significant, and a 0.05 < p < 0.1, a trend.
Results
Allergen-induced inflammation effect on VASP 
phosphorylation
To test the hypothesis that allergen-induced inflamma-
tion would increase phosphorylation of VASP, we exam-
ined the ratio of phosphorylated 50 KD to 46 KD VASP in
epithelium from allergic asthmatic and nonallergic non-
asthmatic normal subjects before and after segmental
allergen challenge in the recovery from injury protocol
(Table 2). The ratio of 50/46 KD VASP in epithelial cells
of both asthmatic and normal subjects increased after Ag
challenge (p = 0.08 for the effect of day on 50/46 KD VASP
ratio), but did not reach significance in either group (Fig-
ure 2). Co-culture of epithelial cells with autologous BAL
cells within the asthmatic subjects did significantly elevate
the 50/46 KD VASP ratio (p = 0.022), but not within non-
asthmatic normal subjects. The total VASP expression (46
KD + 50 KD relative to an internal 76 KD protein [18])
Western blot of bronchial epithelial cells demonstrating 50  and 46 KD isoforms of VASP Figure 1
Western blot of bronchial epithelial cells demon-
strating 50 and 46 KD isoforms of VASP. Representa-
tive western blot of bronchial epithelial cells from an 
asthmatic subject developed with anti-VASP antibody to 
show the banding pattern for the 46 KD and phosphorylated 
50 KD isoforms of VASP. Bronchial epithelial cells received 
either no treatment for 2 or 24 hr or treatment with 10-7 
albuterol for 2 or 24 hr. The treatment with albuterol 
increased the band density for the 50 KD VASP isoform rela-
tive to the 46 KD isoform, greater at 2 hr than after 24 hr 
chronic albuterol treatment.
VASP phosphorylation in epithelial cells of asthmatic and nor- mal control subjects following allergen challenge Figure 2
VASP phosphorylation in epithelial cells of asthmatic 
and normal control subjects following allergen chal-
lenge. Ratio of 50/46 KD VASP in epithelial cells of asth-
matic (squares) and nonasthmatic normal subjects (circles) 
from before (Day 1) and after segmental allergen challenge 
(Days 2, 9 and 16). Epithelial cells were cultured for 24 hr 
with (dashed lines) or without (solid lines) BAL cell co-cul-
ture. Segmental allergen challenge increased the phosphor-
ylation of VASP in asthmatic and normal epithelial cells but 
did not reach significance (p = 0.08). BAL cell co-culture 
exerted a significant effect on VASP phosphorylation in asth-
matic (p = 0.022) but not normal epithelial cells. Neverthe-
less, asthmatic epithelial cells had significantly less VASP 
phosphorylation (lower 50/46 KD VASP ratio) at all time-
points compared to nonasthmatic normal epithelial cells (p < 
0.001 without BAL cells; p = 0.006 with BAL cells).Respiratory Research 2006, 7:25 http://respiratory-research.com/content/7/1/25
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was also examined, but did not significantly differ
between asthmatics' and normals' epithelial cells (p =
0.55), over the 4 timepoints (p = 0.87), or with BAL cell
co-culture (p = 0.97) (data not shown). Asthmatic epithe-
lial cells however, had a significantly lower ratio of 50/46
kD VASP compared to normal epithelial cells at baseline
and throughout the two weeks post-challenge, both with-
out BAL cell co-culture (p < 0.001) and with BAL cell co-
culture (p = 0.006).
Regular inhaled β2-agonist effect on VASP phosphorylation
To test the hypothesis that regular inhalation of β2-agonist
in asthmatics would increase VASP phosphorylation, we
examined the ratio of 50 KD to 46 KD VASP before and
after two weeks regular in vivo use of albuterol or placebo,
and after an additional one week of regular use terminat-
ing 12 hr before the final bronchoscopy (Table 3). After
two weeks inhaled regular β2-agonist use, the 50/46 KD
VASP ratio was increased at day 18–19 for both unchal-
lenged and Ag challenged segments' epithelium (effect for
day, p = 0.009; day 18–19 versus day 1–2, p = 0.07; day
18–19 versus day 25, p = 0.008), but not after placebo (p
= 0.79) in epithelial cells without BAL cell co-culture (Fig-
ure 3). The VASP ratio overall was greater in the Ag chal-
lenged lung segment versus the unchallenged lung
segment (p = 0.017) in the β-agonist protocol (Figure 3A),
but there was no statistical interaction for the effect of day
with the lung segment, either challenged or unchallenged.
To confirm that the epithelial cells from asthmatics
responded to both short and long-acting β2-agonists, aliq-
uots of epithelium from four asthmatics at baseline were
stimulated in vitro with either 10-7 M albuterol, 10-7 M sal-
meterol or unstimulated for 2 hr, and analyzed for 50/46
KD VASP. The VASP ratio in epithelial cells of all asthmat-
ics was significantly increased by albuterol compared to
unstimulated, but not by salmeterol (50 KD/46 KD VASP:
10-7 M albuterol = 0.267 ± 0.06; 10-7 M salmeterol = 0.36
± 0.14, unstimulated = 0.11 ± 0.04; p = 0.018 for albuterol
vs unstimulated, p = 0.13 for salmeterol vs unstimulated).
To determine whether the significant increase in VASP
phosphorylation resulted in altered epithelial cell attach-
ment, the numbers of epithelial cells in bronchoalveolar
lavage fluid were quantitated and compared between reg-
ular albuterol use and placebo. Cells in lavage fluid from
unchallenged lung segments were examined to avoid epi-
thelial shedding due to the allergen-induced inflamma-
tion in challenged segments. Day 18 BAL leukocyte
differential counts did not change from baseline, indicat-
ing no spillover of inflammatory response into the
unchallenged lung segment (p = 0.44 for eosinophils, p =
0.56 for neutrophils, p = 0.28 for lymphocytes). Signifi-
cantly increased numbers of Alcian blue-stained, mucin
containing epithelial cells were observed in the lavage
fluid of unchallenged segments of asthmatics after 2
weeks of β2-agonist, but not placebo (p < 0.001 for group,
p = 0.014 for day and p = 0.004 for group × day interac-
tion) (Figure 4). The number of mucin-containing cells
correlated with the 50/46 KD VASP ratio observed (R =
0.577, p = 0.049). Concomitantly, significantly increased
total epithelial cell numbers in lavage fluid were observed
for β2-agonist but not placebo (p < 0.001 for group, and p
= 0.014 for group × day interaction).
VASP phosphorylation in epithelial cells of asthmatics after  regular albuterol or placebo inhalation Figure 3
VASP phosphorylation in epithelial cells of asthmat-
ics after regular albuterol or placebo inhalation. Ratio 
of 50/46 KD VASP in asthmatic epithelial cells without BAL 
cell co-culture from subjects either on regular albuterol inha-
lation (A) or on regular placebo inhalation (B). Epithelial cells 
were obtained from unchallenged lung segments (Days 1, and 
18, broken lines), from Ag challenged lung segments (Days 2, 
and 19, solid lines) and from resampled lung segments on 
Day 25 (unchallenged Day 1 segment, and challenged Day 2 
segment). Two weeks of regular β2-agonist inhalation, but 
not placebo inhalation, resulted in significantly increased 
phosphorylation of VASP in both unchallenged and chal-
lenged lung segments' epithelium (p = 0.009). Overall, VASP 
phosphorylation, i.e. a larger 50/46 KD VASP ratio, was 
greater in epithelium from challenged than from unchallenged 
lung segments in the regular β2-agonist inhalation protocol (p 
= 0.017), but not in the placebo inhalation protocol (B panel).Respiratory Research 2006, 7:25 http://respiratory-research.com/content/7/1/25
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β2-adrenergic receptor haplotype and VASP 
phosphorylation
Different haplotypes of the β2-adrenergic receptor are
reported to alter receptor expression and in vivo respon-
siveness [27]. Thus, we determined β2-adrenergic receptor
haplotypes of the asthmatic and nonasthmatic normal
subjects, to examine whether the differences in baseline
epithelial VASP phosphorylation between asthmatic and
normal subjects might be due to increased representation
of a particular β2-adrenergic receptor haplotype. Addi-
tional asthmatic and normal subjects, for whom both
haplotype and 50/46 KD VASP data were available, were
added to above subjects (Table 4). The overall 50/46 KD
VASP ratio (mean ± sem) was significantly increased in
nonasthmatic normal versus asthmatic subjects (0.38 ±
0.02 versus 0.16 ± 0.01, respectively; p < 0.001, two-tailed
t test) as observed above (Figure 2). Asthmatic subjects
tended to have several less frequent β2-adrenergic receptor
haplotypes (for example: 1, 9, 10, and 12) than normals,
and more often had the 4/4 homozygous haplotype,
which has arginine at amino acid 16 [25,27]. The 4/4 hap-
lotype is reported to be less responsive to β2-agonist [27].
Nevertheless, these haplotypes did not appear to substan-
tially effect the 50/46 KD VASP ratio. A comparison of the
more frequent 2/4 heterozygous haplotype for the 50/46
KD VASP ratio still remained different: 0.41 ± 0.07 nonas-
thmatic normals versus 0.16 ± 0.04 asthmatic subjects (p
= 0.002, two-tailed t test).
Discussion
Recent investigations into asthma pathogenesis have
begun to focus, not on the acute inflammatory events
involved with asthmatic airway inflammation, but on
aberrant repair mechanisms which appear to be present
[28-30]. This work focused on vasodilator-stimulated
phosphoprotein (VASP) which is predicted to be involved
in epithelial repair mechanisms by mediating focal adhe-
sion, actin filament binding and polymerization, and ulti-
mately, epithelial cell mobility. Reports published during
the course of our studies have shown that detachment of
kidney epithelial cells increases protein kinase A activity
and its phosphorylation of VASP [12], as well as a tran-
sient increase in VASP expression [31]. Although there
was some increase in total VASP (46 KD + 50 KD forms)
in asthmatics compared to normals on day 2 in the recov-
ery from injury protocol, the difference was not signifi-
cant, and probably does not contribute substantially to
cell adherence and motility. We hypothesized that asth-
matics would demonstrate increased VASP phosphoryla-
tion compared to nonasthmatic, normal subjects to
permit actin remodeling and cell migration for repair of
inflammatory injury. Instead, we observed a potential
defect as shown by decreased VASP phosphorylation in
asthmatic epithelial cells prior to and following allergen-
induced injury compared to normal subjects. Increased
VASP phosphorylation in response to segmental antigen
challenge was modest in both asthmatic and nonasth-
matic normal epithelial cells, but overall a profound
decrease in the VASP phosphorylation was observed in
asthmatic epithelial cells at all time points examined. The
reduced VASP phosphorylation in epithelial cells of asth-
matics was confirmed by expanded examination of an
additional group of subjects, both asthmatic and normal
(Table 4). It has been previously shown that blocking of
phosphorylation at MENA Ser 236, which corresponds in
molecular structure to VASP Ser 157, or depletion of ENA/
VASP results in increased cell spreading and reduced func-
tional control of cell motility in a number of model sys-
Numbers of epithelial cells in control segment BAL fluid from  asthmatics before and after regular β-agonist or placebo  inhalation Figure 4
Numbers of epithelial cells in control segment BAL 
fluid from asthmatics before and after regular β-ago-
nist or placebo inhalation. Epithelial cell numbers in 
unchallenged lung segment BAL fluid prior to any inhalation 
(A, day 1) and in unchallenged lung segment BAL fluid after 
two weeks regular inhalation of albuterol or placebo (B, day 
18). The numbers of cells stained with Alcian Blue for 
mucous (gray shaded bars), nonspecific esterase for ciliated 
(hatched bars), other columnar cells (open bars) and the 
total of these three (solid bars) per ml were increased after 
two weeks of regularly inhaled albuterol compared to pla-
cebo (p < 0.001 for both Alcian blue and total groups). There 
was also a significant effect for day in Alcian blue stained cells 
(day 1 versus day 18, p = 0.014) and a significant group × day 
interaction in Alcian blue and total cell groups for albuterol 
inhalation (p = 0.004 and p = 0.014, respectively).Respiratory Research 2006, 7:25 http://respiratory-research.com/content/7/1/25
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tems [3-5,11]. More directly, 10 µM PGE1 converts 60% of
the 46 KD VASP to 50 KD VASP and completely inhibits
platelet aggregation as a measure of cell-cell adhesion [6].
Thus, even partial conversion of VASP to its phosphor-
ylated form has significant impact. This suggests one
potential mechanism for aberrant epithelial repair in asth-
matics: defective or diminished VASP phosphorylation
may indicate abnormal epithelial motility. Confirming
defective epithelial cell motility in asthmatics in vivo will
be challenging, but is a necessary next step in this work.
While segmental antigen challenge did not significantly
increase VASP phosphorylation in the recovery from
injury protocol "a", there was a trend toward a significant
increase, which was confirmed in asthmatics enrolled in
the regular β-agonist inhalation protocol "b". In addition,
leukocytes in bronchoalveolar lavage fluid from asthmat-
ics co-cultured with autologous epithelium did signifi-
cantly increase VASP phosphorylation, unlike the
leukocytes from nonasthmatic normal subjects, suggest-
ing a soluble signal from the BAL leukocytes to epithelial
cells in asthmatics. What the signal(s) may be remains to
be determined, but other work from our laboratory sug-
gests certain growth factors such as TGFβ, could be
involved.
Because VASP becomes phosphorylated by cAMP-depend-
ent protein kinase, we also hypothesized that both in vivo
and in vitro exposure of epithelial cells to a β-agonist,
which increases cyclic AMP levels, should increase VASP
phosphorylation. As predicted, regularly inhaled
albuterol increased VASP phosphorylation in vivo and
apparently altered epithelial cell adhesion, producing sig-
nificantly greater numbers of epithelial cells shed into
bronchoalveolar lavage fluid from unchallenged lung seg-
ments exposed only to the β-agonist, without any aller-
gen-induced inflammation. The β-agonist effect on VASP
phosphorylation was short-lived and the ratio of 50/46
KD VASP returned to baseline within 12 hr of the last
albuterol inhalation in vivo. Whether the increased epi-
thelial cell detachment induced by albuterol inhalation
returns to baseline as quickly has not been determined. β-
agonist use may therefore produce conflicting effects on
asthmatic epithelium. β-agonists inhibit keratinocyte
migration by β2-adrenergic receptor activation of the ser-
ine/threonine phosphatase PP2A [32], the principal phos-
phatase which dephosphorylates VASP [33], and at the
same time activate cAMP-dependent protein kinase phos-
phorylation of VASP [6-9]. Thus, β-agonists may promote
epithelial repair by enhancing both phosphorylation and
dephosphorylation of VASP in actin filament restructur-
ing, but may also promote epithelial damage by increas-
ing the detachment of epithelial cells from the airway.
These results also caution against considering as "base-
line" or "control," samples obtained from asthmatics
receiving β-agonist therapy without an appropriate wash-
out interval.
Genetic variation and altered function of the β2-adrener-
gic receptor could potentially contribute to the differences
in VASP phosphorylation observed between asthmatics
and nonasthmatic normal subjects [27]. However, exami-
nation of 50/46 KD VASP ratio grouped according to β2-
adrenergic receptor haplotype for our study subjects did
not reveal any specific haplotype bias, either homozygous
or heterozygous, affecting VASP phosphorylation.
Although the numbers of subjects in any one haplotype
classification were limited, the largest 2/4 haplotype
group, nonasthmatic normal subjects showed a signifi-
cantly increased ratio compared to asthmatic subjects. It is
possible that other characteristics of the β2-adrenergic
receptor gene (for example, stability of message due to
variation in the 3' untranslated region, [34]), variation in
other components in the signaling cascade such as cAMP
dependent protein kinase A [6-9], or activation of protein
kinase C [10], genetic variation in VASP itself, or differ-
Table 4: Mean of 50 KD/46 KD VASP ratio in epithelial cells according to β2-adrenergic receptor haplotype. Specific β2-adrenergic 
receptor haplotypes are shown with the mean ratio of 50/46 KD VASP for nonasthmatic normals or asthmatics having that haplotype. 
Asthmatics tended to have haplotype 4 which contains Arg at amino acid 16, and rarer haplotypes such as 1, 9, and 10 than 
nonasthmatic normals. The overall reduced phosphorylation of VASP (higher 50/46 KD ratio) in asthmatics compared to normals does 
not appear associated with a specific haplotype.
Haplotype 2/2 2/4 2/6 4/4 4/6 6/10 1/1 4/(1,9,12)* 4/10 1/10 6/9
Normal:
Total N = 17 N = 6 N = 5 N = 3 N = 1 N = 1 N = 1
Mean 50/46 KD .307 .408 .455 .475 .168 .491
± SEM ± 0.07 ± 0.07 ± 0.10
AsthmaTic:
Total N = 30 N = 2 N = 9 N = 8 N = 3 N = 1 N = 2 N = 3 N = 1 N = 1
Mean 50/46 KD .230 .163† .164 .147 .187 .233 .110 .094 .046
± SEM ± 0.01 ± 0.04 ± 0.03 ± 0.07 ± 0.00 ± 0.02
*The haplotyping method could not distinguish among these infrequent haplotypes (1, 9, and 12)
†Asthmatics versus Normals, p = 0.002 (two-tailed t test, equal variance)Respiratory Research 2006, 7:25 http://respiratory-research.com/content/7/1/25
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ences in the activity of protein phosphatases [33] between
asthmatics and normals may contribute to the observed
disparity in VASP phosphorylation here between asth-
matic and normal subjects. Work is currently addressing
these areas of inquiry.
Conclusion
Phosphorylation of VASP is significantly reduced in bron-
chial epithelial cells from asthmatics compared to nonas-
thmatic normal subjects, although inducible by β-agonist
treatment either in vitro or in vivo. The reduced ratio of
phosphorylated to unphosphorylated VASP in asthmatics
does not appear associated with genetic variation in the
β2-adrenergic receptor. Regular inhalation of β-agonist
results in increased VASP phosphorylation in epithelial
cells and increased epithelial cell detachment from the air-
ways.
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